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ARDS = acute respiratory distress syndrome; BALF = bronchoalveolar lavage fluid; DPPC = dipalmitoylated phosphatidylcholine; FiO2 = fraction of
inspired oxygen; γmin = minimum surface tension after 5 min of film oscillation; IRDS = infant respiratory distress syndrome; LA = large surfactant
aggregate; PaO2 = partial pressure of arterial oxygen; PL = phospholipid; SP-A/B/C/D = surfactant apoprotein A/B/C/D; V/Q = ventilation/perfusion.
Available online http://respiratory-research.com/content/2/6/353
Introduction
Acute respiratory distress syndrome
The acute respiratory distress syndrome (ARDS) describes
an overwhelming inflammatory reaction within the pulmonary
parenchyma leading to life-threatening disturbances in pul-
monary vasomotion, alveolar ventilation, and gas exchange.
Originally, this syndrome was described in 1967 by Ash-
baugh and collegues [1]. According to the recent Ameri-
can–European Consensus Conference [2], ARDS is
defined by an acute onset (catastrophic event), an oxygena-
tion index (ratio of the partial pressure of arterial oxygen to
the fraction of inspired oxygen [PaO2/FiO2 ]) <200 mmHg,
bilateral infiltrates on chest radiography, and a pulmonary
capillary wedge pressure <18 mmHg or absence of clinical
evidence for left-sided heart failure. When the PaO2/FiO2
ratio is between 200 and 300 mmHg and the other above-
mentioned criteria are met, the term ‘acute lung injury’ (ALI)
should be used instead of ARDS. ARDS is a frequent
disease (incidence between 13.5 [3] and 75 per 100,000
[4]), thus affecting about 16–18% of all patients ventilated
in the intensive care unit [3]. Despite recent progress in the
understanding of the disease and numerous efforts to
develop causative or symptomatic treatment options, ARDS
still has a high mortality rate of about 30–40% [5].
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Abstract
The acute respiratory distress syndrome (ARDS) is a frequent, life-threatening disease in which a
marked increase in alveolar surface tension has been repeatedly observed. It is caused by factors
including a lack of surface-active compounds, changes in the phospholipid, fatty acid, neutral lipid, and
surfactant apoprotein composition, imbalance of the extracellular surfactant subtype distribution,
inhibition of surfactant function by plasma protein leakage, incorporation of surfactant phospholipids and
apoproteins into polymerizing fibrin, and damage/inhibition of surfactant compounds by inflammatory
mediators. There is now good evidence that these surfactant abnormalities promote alveolar instability
and collapse and, consequently, loss of compliance and the profound gas exchange abnormalities seen
in ARDS. An acute improvement of gas exchange properties together with a far-reaching restoration of
surfactant properties was encountered in recently performed pilot studies. Here we summarize what is
known about the kind and severity of surfactant changes occuring in ARDS, the contribution of these
changes to lung failure, and the role of surfactant administration for therapy of ARDS.
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ARDS may develop after a direct injurious attack on the
lung parenchyma (direct ARDS) or may result from inflam-
matory processes carried into the lung via the pulmonary
vasculature (indirect, ‘classic’ ARDS; see Supplementary
Table 1). Inhaled or aspirated noxious agents, e.g. toxic
gases or gastric contents, induce an inflammatory
response in the epithelial and later the interstitial and
endothelial compartments of the lung. On the other hand,
numerous systemic disorders may induce an overwhelm-
ing inflammatory response that may be transferred to the
lungs via cellular and humoral mediators entering the pul-
monary circulation [6]. One such trigger mechanism is
sepsis, leading to respiratory distress in about 43% of
these sepsis patients [7].
In the early, exudative, phase of ARDS, the massive, self-
perpetuating inflammatory process involves the entire gas
exchange unit (see Supplementary Fig. 1). Pathophysio-
logically, this phase has four characteristics: an increase in
capillary endothelial and/or alveolar epithelial permeability;
leakage of plasma protein, with flow of edematous fluid
into the interstitial and, later, the alveolar spaces; vasocon-
striction and microembolism or microthrombosis in the
vascular compartment, and thus increased pulmonary vas-
cular resistance, with maldistribution of pulmonary perfu-
sion; and an increase in alveolar surface tension favoring
alveolar instability with formation of atelectasis and ventila-
tory inhomogeneities. As a consequence, a profound ven-
tilation/perfusion (V/Q) mismatch, with extensive
intrapulmonary shunt flow and highly impaired gas
exchange, is regularly seen. This exudative phase may
persist for about a week, during which full recovery
without persistent loss of lung function is very possible [8]
(see Supplementary Fig. 1). However, new inflammatory
events, such as recurrent sepsis or acquisition of sec-
ondary (nosocomial) pneumonia, may repetitively worsen
the state of lung function and then progressively favor pro-
liferative processes characterized by mesenchymal cell
activation and ongoing lung fibrosis [9] (see Supplemen-
tary Fig. 1). Fibroproliferative events such as increased
collagen matrix production occur early in the course of
ARDS (about 5 to 7 days after the onset [10]) and may
lead to irreversible, restrictive abnormalities of lung func-
tion. In addition, the development of pulmonary fibrosis
and deposition of extracellular collagen in the alveolar
space correlates with an increased risk of death in ARDS
[11,12] (see Supplementary Fig. 1).
Pulmonary surfactant system
Pulmonary surfactant is a lipoprotein complex covering
the alveolar surface of all mammalian lungs [13]. By pro-
foundly reducing the surface tension at the air–water
interface, it makes alveolar ventilation and gas exchange
feasible at physiologic transpulmonary pressures and
prevents alveoli from collapsing, in particular during
expiration.
Pulmonary surfactant consists of about 90% lipids and
about 10% proteins. Of the lipids, about 10–20% are
neutral. The rest (80–90%) are phospholipids (PLs), of
which about 80% are phosphatidylcholine, which contains
an unusually large amount of palmitic acid residues (about
50–60% of all phosphatidylcholine molecules are dipalmi-
toylated [DPPC]) and about 10% are phosphatidylglycerol.
Other PLs regularly found in low percentages are phospha-
tidylethanolamine, phosphatidylserine, phosphatidylinositol,
and sphingomyelin.
Four surfactant-specific apoproteins have been discovered
so far, called surfactant apoprotein (SP)-A, SP-B, SP-C
[14], and SP-D [15]. SP-B and SP-C are extremely
hydrophobic, low-molecular-weight proteins, whereas SP-A
and SP-D are hydrophilic, high-molecular-weight proteins
belonging to the family of collectins (C-type lectins). Upon
the inspiratory stretch of the alveolar cell layer, alveolar type
II pneumocytes secrete surfactant-containing lamellar
bodies into the alveolar hypophase, which are then reorga-
nized into the highly surface-active tubular myelin [16] and
large, multilamellar vesicles. Lamellar bodies, tubular
myelin, and large, multilamellar vesicles are called large sur-
factant aggregates (LAs). Adsorption of PLs to the
air–water interface results in the formation of a stable PL
film. During breathing, when the surface film is compressed
and re-expanded, film compounds are squeezed out,
leading to a dense packing of ‘rigid’ lipid material such as
DPPC and thus to extremely low surface tension values
(near 0 mN/m). Next to DPPC and phosphatidylglycerol,
the hydrophobic apoproteins SP-B and SP-C seem to play
an essential role for these adsorption facilities and dynamic
surface-tension-lowering properties [13]. Additional func-
tions of the alveolar surfactant system include prevention of
alveolar edema [17] and a pronounced influence, espe-
cially of the collectins SP-A and SP-D, on pulmonary host
defense mechanisms (reviewed [18,19]).
Surfactant deficiency has been established as the primary
cause of the respiratory failure in infant respiratory distress
syndrome (IRDS) [20], and transbronchial application of
surfactant preparations has become the gold standard for
the treatment of this disorder [21]. In ARDS, however, sur-
factant deficiency seems not to be of major importance;
rather, a broad spectrum of biochemical and biophysical
surfactant abnormalities contributes to respiratory failure.
Alteration of the pulmonary surfactant
system in acute respiratory distress
syndrome
The first, indirect, evidence of a severe impairment of sur-
factant function in ARDS was provided in 1979 by Petty
and co-workers, who examined lungs from patients who
had died from respiratory failure [22]. In more recent
studies, using bronchoalveolar lavage fluid (BALF) from
ARDS patients, impairment of the surface-tension-lower-c
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ing properties was consistently noted [23–26], with
minimum surface tension values being increased to
15–20 mN/m, instead of <5 mN/m as observed in healthy
volunteers (Fig. 1). Similarly elevated values were found
for surfactant samples obtained from patients at risk of
ARDS [25]. Unlike the case in IRDS, in which the initial
lack of surface-active material triggers the pathophysio-
logic sequelae, more complex changes of the biophysical
and biochemical surfactant properties were noticed: these
included alteration of the PL and fatty acid profile,
decreased levels of surfactant apoproteins, reduced
content of LA, inhibition of surfactant function by leaked
plasma proteins, and inhibition by inflammatory mediators.
Lack of surface-active compounds and alteration of
phospholipid, fatty acid, and apoprotein profiles
Clinical studies addressing the PL composition of BALF
samples from patients with ARDS [23–26] revealed three
important features (Table 1). Firstly, in two of four studies,
the overall PL content was reduced. Secondly, a signifi-
cant change in the relative distribution of the PL classes
was noted throughout, including a marked decrease in
phosphatidylglycerol levels (by >80% in three of the
studies) and a compensatory increase in the relative
amounts of the minor components (phosphatidylinositol,
phosphatidylethanolamine, phosphatidylserine, sphin-
gomyelin). However, phosphatidylcholine, the most abun-
dant PL, was reduced only moderately throughout the
studies. Thirdly, the relative amount of palmitic acid, the
major fatty acid of phosphatidylcholine, was significantly
decreased, to about 80% of control values, whereas the
relative amount of unsaturated fatty acids in this PL was
increased [27]. The relative amount of DPPC, the most
abundant single surfactant component, was dramatically
reduced (to half that in controls).
Because of the late detection of surfactant apoproteins and
– in the case of SP-B and SP-C – their extreme hydrophobic
nature, appropriate analytical techniques for the quantifica-
tion of these essential compounds under clinical conditions
have only recently become available. Four studies measuring
them in patients with ARDS demonstrated an impressive
decline of SP-A, but not of SP-D [24–26,28] (Table 2). Con-
centrations of SP-B and SP-C were markedly reduced in the
original BALF from ARDS patients [28] and particularly
within the LA fraction [25,29]. SP-A and SP-B levels
remained depressed for at least 14 days after the onset of
ARDS [28]. Interestingly, a decrease of these functionally
important compounds was also observed in patients at risk
for ARDS [25,28] (see Table 2).
The reported changes of the biochemical surfactant com-
position (PLs, fatty acids, apoproteins) in ARDS are likely
to reflect injury of alveolar type II cells, with consequently
altered metabolism or secretion of lipid and apoprotein by
these cells.
Altered distribution of surfactant subtypes
Under physiologic conditions, some 80–90% of the extra-
cellular surfactant material is recovered in the LA fraction
that is characterized by a high SP-B content and excellent
surface activity. However, in experimental lung injury [30]
and in acute inflammatory lung diseases (severe pneumo-
nia, ARDS) [26,29,31], an increase of small surfactant
aggregates is is paralleled by a loss of SP-B and surface
activity within the LA fraction. These small aggregates are
far less surface-active and are considered to represent
degradation products of the interfacial film.
The underlying reason for this imbalance in the distribution
of surfactant subtypes is poorly understood. Decreased
secretion of freshly synthesized or recycled surfactant
material by alveolar type II cells, degradation of LAs due to
inflammatory mediators, and accelerated large-to-small
surfactant aggregate conversion are offered as putative
mechanisms. Concerning the latter, the requirement of an
enzymatic activity was proposed on the basis of inhibitor
Available online http://respiratory-research.com/content/2/6/353
Figure 1
Biophysical surfactant properties of isolated large surfactant
aggregates from healthy volunteers (Control) and patients with
cardiogenic lung edema (CLE), ARDS (with extrapulmonary trigger),
severe pneumonia necessitating mechanical ventilation (PNEU), or
ARDS and lung infection (ARDS + PNEU). Surface tension [mN/m] at
minimum bubble size after 5 min of film oscillation (γmin) is given
(pulsating bubble surfactometer, at 2 mg/ml phospholipid). Single
events (circles), means (triangles), and medians (squares) are
indicated. ***(P < 0.001). From [26], with permission.studies employing serine protease inhibitors [32]. A diiso-
propylfluorophosphate-binding protein, later named ‘con-
vertase’, was isolated from BALF, purified, and
characterized as a member of the carboxylesterase family
[33,34]. The physiologic substrate of the esterase,
however, is presently unknown. Because of the broad sub-
strate specificity of carboxylesterases, lipids and proteins
could both be targets. The assumption that DPPC, the
most abundant and biophysically most important PL, is the
substrate was recently disproved [35]. Other data
suggest that SP-B may be a candidate for the convertase
attack, thereby promoting LA conversion [29,36]. At
present, there is no information available as to the regula-
tion of the convertase in acute or chronic inflammatory
lung diseases (see Supplementary Fig. 2).
Inhibition of surfactant function by plasma protein
leakage
Leakage of plasma proteins into the alveolar space
because of impaired function of the air–blood barrier con-
sisting of capillary endothelium and alveolar epithelium is a
very early event in the pathogenesis of ARDS and may
substantially contribute to surfactant alterations in ARDS.
Experimental studies in vitro and in vivo have shown that
admixture of blood, serum, plasma, or alveolar washings
obtained during states of plasma leakage may severely
compromise biophysical surfactant function. Among the
proteins involved, albumin [37–39], hemoglobin [40], and
in particular fibrinogen or fibrin monomers [37–39,41,42]
possess strong surfactant inhibitory properties. These
studies also showed that the degree of inhibition of surfac-
Respiratory Research    Vol 2 No 6 Günther et al.
Table 1
Phospholipid (PL) content and profile in patients with acute respiratory distress syndrome (ARDS) and in other subjects
Hallmanet al. [23]a Pison et al. [24]b Gregory et al. [25]c Günther et al. [26]b
Low- High- ARDS
score score +
PL Normal ARDS Normal ARDS ARDS Normal At risk ARDS Normal ARDS PNEU PNEU
Total 0.6 0.6 84.1 65.7 65.1 7.99 3.48 2.47 29.38 28.11 22.57 21.82
µM µM µg/ml µg/ml µg/ml µmol/ml µmol/ml µmol/ml µg/ml µg/ml µg/ml µg/ml
PC 73 59.5 62.8 56.3 48.1 76.27 73.32 62.64*** 83.1 81.9 76.8 79.2
PG 12.4 0.3*** 10.02 1.6 1.88 11.58 7.26 6.48*** 8.6 3.5*** 2.4*** 5.2**
PI 2.7 3.1 8.32 13.54 13.95 3.88 4.71 6.94** 3.2 6.5* 8.0*** 5.5*
PE 2.6 4.3 4.82 13.65 18.68 3.32 4.9 5.86* 1.7 1.9 2.6 2.4
PS 3.3 13.0*** 4.5 n.d. n.d. 1.8 3.75 2.84 1.2 1.8 1.7 2.4
Sph 3.7 17.5*** 7.37 12.28 14.21 1.45 1.56 5.45*** 0.8 3.5** 5.2*** 4.3***
LPC 0.4 1.5 1.3 1.7 1.0 0.16 1.34 2.32* 0.1 0.3 0.2 0.2
aBALF post sucrose density gradient centrifugation at 100,000 × g (lipid–protein complex) was used. bOriginal BALF after cell separation (300 ×
g) was used. cCell-depleted BALF post centrifugation at 48,000 × g (‘crude surfactant pellet’) was used. The relative amount (mean values) of
each PL is given as percentage of total PL. *P < 0.05, **P < 0.01, ***P < 0.001. BLAF = bronchoalveolar lavage fluid; LPC =
lysophosphatidylcholine; n.d. = not determined; PC = phosphatidylcholine; PE = phosphatidylethanolamine; PG = phosphatidylglycerol; PI =
phosphatidylinositol; PNEU = pneumonia; PS = phosphatidylserine; Sph = sphingomyelin.
Table 2
Surfactant apoprotein content in patients with acute respiratory distress syndrome (ARDS) and in other subjects
Pison et al. [24]a Gregory et al. [25]b Günther et al. [26]a Greene et al. [28]a
Surfactant ARDS + ARDS ARDS
apoprotein Normal ARDS Normal At risk ARDS Normal ARDS PNEU PNEU Normal At risk (day 1) (day 14)
SP-A (µg/ml) 2.74 1.49 123.64 49.28*** 29.88*** 1.533 0.849* 0.747** 0.876** 4.813 1.200*** 1.224*** 1.132***
SP-B (ng/ml) n.m. n.m. 1.28 0.89 0.57*** 740 867 818 737 109.5 44.3*** 37.2*** 31.4***
SP-D (µg/ml) n.m. n.m. n.m. n.m. n.m. n.m. n.m. n.m. n.m. 1.034 0.868 1.080 1.220
aBALF was centrifuged for cell removal; concentration is indicated for original lavage fluid. bCell-free BALF was concentrated by centrifugation at
48,000 × g; concentration is indicated for ‘crude surfactant pellet’. Values are means. *P < 0.05, **P < 0.01, ***P < 0.001. BALF =
bronchoalveolar lavage fluid; n.m. = not measured; PNEU = pneumonia; SP-A/B/D = surfactant apoprotein A/B/D.tant function by fibrinogen depends on the surfactant
apoprotein profile. Surfactant preparations lacking the
hydrophobic apoproteins are extremely sensitive to fibrino-
gen inhibition, and less sensitivity is noted in the presence
of SP-B and SP-C in near-physiologic quantities [42,43].
In addition, further improvement in protein resistance is
achieved by supplementation of PL- and hydrophobic-
apoprotein-based surfactants with SP-A [39].
Incorporation of surfactant in fibrin/hyaline membranes
Accumulation of fibrin-rich material (‘hyaline membranes’) is
commonly found in ARDS and other acute or chronic inter-
stitial lung diseases [10,44,45]. In acute or chronic inflam-
matory conditions, the alveolar hemostatic balance is
shifted towards predominance of a procoagulant activity,
which is almost exclusively attributable to tissue factor and
factor VII [46–48]. In contrast, the fibrinolytic activity of the
alveolar space was found to be markedly reduced in these
conditions, with reduced concentrations of urokinase, the
predominant plasminogen activator in this compartment
[46,48,49], but elevated activities of plasminogen activator
inhibitor 1 (PAI-1) and α2-antiplasmin [46,47,49]. Hence,
rapid fibrin formation is to be expected under these condi-
tions. Recently, this group demonstrated loss of surfactant
PLs from the soluble phase due to binding to or within
fibrin strands when fibrin polymerized in the presence of
surfactant material; this loss was paralleled by a virtually
complete loss of surface activity [50] (Fig. 2). By this mech-
anism, the surfactant-inhibitory capacity of polymerizing
fibrin was found to surpass that of soluble fibrin monomers
or fibrinogen by more than two orders of magnitude, thus
representing the most effective surfactant inhibitory mecha-
nism hitherto described for plasma proteins. Overall, the
findings obviously suggest that PLs and hydrophobic
apoproteins are incorporated into the growing fibrin matrix,
with severe loss of biophysically important surfactant com-
pounds in areas with alveolar fibrin and hyaline membrane
formation. In addition, fibrin clots embedding natural surfac-
tant display markedly altered mechanical properties [51]
and reduced susceptibility to proteolytic degradation [52].
Surface activity can be largely restored by application of
fibrinolytic agents in vitro [53] and in vivo [54], with the
release of formerly incorporated surfactant material into the
soluble phase (see Fig. 2).
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Figure 2
Diagram representing inhibition of pulmonary surfactant by fibrin formation and concept of collapse induration. Under physiological conditions the
phospholipid lining layer at the air–water interface reduces the surface tension and thereby promotes lung expansion upon inspiration and prevents
lung collapse during expiration. In inflammatory diseases (such as ARDS, severe pneumonia) fibrinogen, leaking into the alveolus, is converted into
fibrin due to a pronounced procoagulatory actvity in the alveolar compartment. Surfactant function is greatly inhibited by incorporation of
hydrophobic surfactant components (PL, SP-B/C) into polymerizing fibrin. Persistence of this ‘specialized’ fibrin matrix promotes fibroprolifertive
processes (‘collapse induration’), whereas a complete lysis results in the liberation of intact surfactant material with re-opening of formerly
collapsed alveoli.Damage of surfactant compounds by inflammatory
mediators
A complex network of humoral or cellular effector systems
contributes to the inflammatory response in ARDS. Pro-
inflammatory mediators may be produced locally in the
alveolar compartment by activated neutrophils and
macrophages, lung epithelial cells, or fibroblasts. Free
elastase and collagenase activities [55,56], oxidative inhi-
bition of the alveolar α1-proteinase inhibitor indicating
oxygen radical generation, and increased levels of
lysophospholipids (in particular lysophosphatidylcholine)
[23] suggesting increased phospholipolytic activity have
been encountered in BALF from patients with ARDS.
Degradation of SP-A in BALF from ARDS patients was
recently observed [57], indicating a high proteolytic activ-
ity in the alveolar compartment under inflammatory condi-
tions. In addition, as summarized in Table 3, a variety of in
vitro studies demonstrated a direct surfactant inhibitory
effect for various mediators.
Pathophysiologic consequences of surfactant
alterations in acute respiratory distress
syndrome
As described above, severe alterations of the pulmonary
surfactant system have been observed in the course of
ARDS, favoring an increase in alveolar surface tension.
Thus, the question arises, whether and to what extent
these surfactant abnormalities contribute to pathophysio-
logic events encountered in ARDS.
Alteration in lung mechanics
Loss of surface activity leading to an increased alveolar
surface tension is assumed to cause alveolar instability
and atelectasis. According to the law of Laplace (p = 2 ×
γ × r –1; where p = pressure, γ = surface tension, and r =
radius), an increase in surface tension should result in a
marked decrease of lung compliance. This basic finding
was described in early reports of altered lung mechanics
in patients who died with ARDS [22]. In addition, a
marked decrease in compliance was observed in a variety
of experimental animal models of ARDS, including disor-
ders induced by administration of oleic acid, N-nitroso-N-
methylurethane, or hydrochloric acid, by experimental
induction of pneumonia or sepsis, and by repetitive lung
lavage [58–64]. Transbronchial application of surfactant
completely or partially restored physiologic lung compli-
ance in some of these models. In patients with severe
ARDS, however, lung compliance is still difficult to
measure reliably, mostly because of uncertainties concern-
ing lung volume and transpulmonary pressures.
Respiratory Research    Vol 2 No 6 Günther et al.
Table 3
In vitro studies demonstrating the impact of inflammatory mediators on surfactant function
Mediator Effects
Phospholipases
PL-A2, PL-C Generation of lysophospholipids [94]
Generation of free fatty acids [95]
Loss of surface activity [94]
Higher sensitivity towards inhibition by plasma proteins [96]
Cytokines
TNF-α Pretranslational inhibitory effect on the expression of SP-A and SP-B [97]
Proteases
Elastase Degradation of SP-A, indirect evidence for degradation of SP-B and SP-C; loss of surface activity [98]
Degradation of SP-A, SP-B, SP-C [99]
Trypsin Degradation of SP-A [99]
Surfactant ‘convertase’ Increased conversion of large to small surfactant aggregates [32]
Oxygen radicals
ROS, ozone Decrease in surface activity [100, 101]
Induction of lipid peroxidation [101]
Inhibition of SP-A self-aggregation [102]
Lipid mediators
Arachidonic acid Decrease in surface activity [101]
Activated neutrophils (PMNs) Decrease in surface activity [100]
Degradation of SP-A [100]
PL-A2/-C = phospholipase-A2/-C; PMNs = polymorphonuclear neutrophils; ROS = reactive oxygen species; TNF = tumor necrosis factor.Impairment of gas exchange: V/Q mismatch and shunt
flow
In preterm babies with IRDS, where a lack of surface-
active material triggers the pathophysiologic sequelae,
transbronchial surfactant replacement dramatically
improves gas exchange and arterial oxygenation [21]. In
experimental removal of endogenous surfactant from the
lung (repetitive lavage models) [65] or surfactant inactiva-
tion with detergent [66], gas exchange properties deterio-
rated severely, and transbronchial application of
exogenous surfactant material restored gas exchange and
improved V/Q matching.
In more realistic models of ARDS, starting with induction
of microvascular or alveolar injury, matters are more
complex. Shunt flow (perfusion of atelectatic regions)
and blood flow through lung areas with low V/Q ratios
(dystelectatic lung regions) may well be related to an
acute impairment of the alveolar surfactant system.
Transbronchial surfactant application was found to
improve gas exchange in models with protein-rich edema
formation due to cervical vagatomy [67], hydrochloric
acid aspiration [58,60], pneumonia [63,64], and applica-
tion of N-nitroso-N-methylurethane [59] or oleic acid
[61]. The most obvious explanation for this improvement
under experimental and also clinical conditions is the
recruitment of formerly collapsed lung regions, with
reduction of shunt flow and of V/Q mismatch [68].
However, in these models in which lung inflammation is
induced, the efficacy of surfactant replacement is less
impressive than in IRDS or IRDS-like models, in which
the surfactant depletion is primary. The difference is
most likely due to the presence of surfactant-inhibitory
agents including leaked plasma proteins and inflamma-
tory mediators, as discussed above. Much larger
amounts of exogenous surfactant are needed to over-
come such inhibitory capacities.
Formation of lung edema
The importance of both epithelial and endothelial injury in
the development of alveolar edema has been established.
Surfactant alterations, however, also may contribute to the
edema. Any increase in surface tension may result in a
decrease in interstitial and thus perivascular pressures.
Transendothelial and, later, transepithelial fluid movement
into the interstitial and, later, alveolar space may increase.
Several experimental studies described formation of exten-
sive lung edema due to inhibition of surfactant function in
vivo by transbronchially applied detergent [17], intratra-
cheally injected bile acid [69], cooling and ventilating at
low functional residual capacity [70], or plasma lavage
[71]. In some of the studies, transbronchially applied sur-
factant reduced alveolar flooding [69]. Concerning
patients with ARDS, however, there is at present no con-
clusive evidence that surfactant abnormalities affect lung
fluid balance in patients with ARDS.
Reduction in host defense competence?
Nosocomial infection/ventilator-associated pneumonia is a
common complication of ARDS (incidences range from
36.5% to 60%) that adversely affects the prognosis
[72,73]. As pulmonary surfactant participates in the alveo-
lar host defense system, alterations of the surfactant
system may contribute to an increased susceptibility of
these patients to secondary lung infection. At present, the
host defense properties of pulmonary surfactant are not
fully understood. Suggested mechanisms include direct
interaction of surfactant components with pathogens
(viruses, bacteria) or their products (e.g. endotoxin, viral
glycoproteins); stimulation of phagocytosis by surfactant
components (as an opsonin or active ligand); influence of
the chemotaxis of immune-competent cells; and regulation
of cytokine release and reactive oxygen production by
macrophages (reviewed [18]). The hydrophilic surfactant
apoproteins SP-A and SP-D have distinct functions in the
innate immune response to microbial challenge. Studies
with SP-A knockout mice revealed that these animals are
more sensitive to infection with Haemophilus influenzae
group B streptococci and Pseudomonas aeruginosa [74].
In addition, the surfactant lipids suppress a variety of
immune cell functions, including activation, proliferation,
and immune response of lymphoctes, granulocytes, and
alveolar macrophages [75,76] and can even promote bac-
terial lysis [77].
Changes in the protein and/or lipid composition of surfac-
tant may thus effect immunomodulation in the lung. As
indicated above, the exact contribution of each surfactant
component to the alveolar host defense system remains
uncertain. Nevertheless, the marked decrease in SP-A
levels [24–26,28] and the proof of degradation of SP-A in
vivo in the lungs of ARDS patients [57] suggest a loss of
opsonizing capacity and increased susceptibilty to noso-
comial infections.
‘Collapse induration’, mesenchymal cell proliferation,
and fibrosis
During the acute phase of ARDS, full recovery without
persistent loss of lung function is possible [8]. However,
some patients progress to a fibroproliferative phase, char-
acterized by mesenchymal cell activation and proliferation,
with synthesis of extracellular matrix components such as
collagen, formation of new blood vessels, and bronchi-
olization [9]. Within a few weeks, structural remodelling of
the lung leads to widespread lung fibrosis and honey-
combing. The onset of the fibroproliferative response is an
early event in ARDS [78,79] and correlates with the
outcome. The pathologic mechanisms underlying such a
rapid fibroproliferative response to an acute inflammatory
event have not been fully elucidated. In addition to inflam-
matory cells [80], cytokines [81,82] and growth factors (in
particular transforming growth factor β [83]), abnormalities
of the pulmonary surfactant system, and deposition of
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fibrosis and honeycombing (Fig. 2). According to the
concept of ‘collapse induration’ as suggested by
Burkhardt [44], lung fibrosis preferentially occurs at sites
of persistent atelectasis due to extensive loss of alveolar
surfactant function and to ‘glueing’ of adjacent septae by
generation of alveolar fibrin. This specialized alveolar fibrin
matrix serves as a nidus for fibroblast invasion, resulting in
the deposition of excess extracellular matrix and irre-
versible loss of alveolar space. Thick, indurated septae (or
conglomerates of several septae) may exist adjacent to
dilated alveoli, providing the typical morphological image
of fibrosis and honeycombing [10]. Additionally, thrombin
[84,85], fibrinopeptides A/B [86], and fibrin(ogen) scis-
sion products [87] have been shown to serve as potent
fibroblast mitogens.
Surfactant replacement in acute respiratory
distress syndrome
Against this background of surfactant abnormalities and
their contribution to the pathophysiology of ARDS,
improvement of alveolar surfactant function appears to be
a reasonable approach to restore gas exchange proper-
ties and lung compliance. Such attempts may include
pharmacological approaches to stimulate secretion of
intact surfactant material from type II cells, protection from
degradation of surfactant compounds, and inhibition of
large-to-small aggregate conversion, but evidence that
these approaches are effective in acute respiratory failure
is still lacking. As in IRDS, transbronchial application of
exogenous surfactant may be used in ARDS to restore
surfactant function in inflamed lungs, but larger quantities
may be needed to overcome the inhibitory (proteinaceous)
Respiratory Research    Vol 2 No 6 Günther et al.
Table 4
Transbronchial surfactant application in acute respiratory distress syndrome (ARDS)
Dosage/Regimen N Effects (versus control or baseline) Study (design)
Curosurf® via bronchoscope 6 Gas exchange (PaO2): ↑ (n.s.) Spragg et al., 1994 [103]
50 mg/kg b.w.  Chest radiograph: ~ (uncontrolled trial)
Lung compliance: ~
Surfactant activity (BALF): ↑
Exosurf® aerosolized for up to 5 days; 725 Gas exchange (PaO2/FiO2): ~ Anzueto et al., 1996 [91]
estimated dose delivered about Survival at 30 days: ~ (prospective, multicenter, 
5 mg/kg per day (control: 0.45% saline) Duration of mechanical ventilation: ~ double-blind, randomized, 
Length of stay in the ICU: ~ placebo-controlled)
Alveofact® via bronchoscope  10 Gas exchange (PaO2/FiO2): ↑ (P < 0.001) Walmrath et al., 1996 [68]
300 mg/kg b.w., augmentation to Shunt flow: ↓ (P < 0.001) (prospective, multicenter, 
500 mg/kg b.w. possible Surfactant activity (BALF): ↑ (P < 0.001) uncontrolled)
Survanta® via intratracheal instillation 43 Gas exchange (PaO2/FiO2): Gregory et al., 1997 [88]
8 × 50 mg/kg b.w. (N = 8) ↑ (n.s., 8 × 50, 4 × 100 mg) (prospective, controlled, 
4 × 100 mg/kg b.w. (N = 16) ↑ (P < 0.01, 8 × 100 mg) randomized, open-label trial)
8 × 100 mg/kg b.w. (N = 19) Mortality: ~ (8 × 50 mg)
(control: no treatment) ↓ (P ≤ 0.075, 4 × 100 mg, 8 × 100 mg)
Surfactant activity (BALF): ↑
Infasurf® via intratracheal instillation 42 Gas exchange (PaO2/FiO2): ↑ (P < 0.05) Willson et al., 1999 [90]
2800 mg/m2 Duration of mechanical ventilation: ↓ (P < 0.03) (prospective, multicenter, 
(children with ARDS)  Days on the PICU: ↓ (P < 0.03) randomized, controlled, 
Days on oxygen: ↓ (P < 0.06) unblinded trial)
Days in hospital: ↓ (P < 0.12)
Mortality: ~
Venticute® via intratracheal instillation 41 Gas exchange (PaO2/FiO2): ↑ (MID) Walmrath et al., 2000 [89]
MID (N = 14) Ventilator-free days: ↑ (MID) (prospective, controlled, 
4 × 50 mg/kg b.w. PL Weaned by day 28: ↑ (MID) randomized, multicenter, 
(= 4 × 1 mg/kg b.w. rSP-C) Mortality: ↓ (MID) open-label trial)
HIGH (N = 15) No differences observed in the HIGH group
1 × 200 + 3 × 100 mg/kg b.w. PL
(= 1 × 4 + 3 × 2 mg/kg b.w. rSP-C)
STD (control): standard treatment (N = 12)
↓ = decreased; ↑ = increased; ~ = unchanged; BALF = bronchoalveolar lavage fluid; b.w. = body weight; FiO2 = fraction of inspired oxygen;n.s. =
not significant; PaO2 = partial pressure of arterial oxygen; (P)ICU = (pediatric) intensive care unit; rSP-C = recombinant surfactant apoprotein C.
Venticute is a synthetic surfactant preparation with a standardized PL and rSP-C content; the dosage in pairs refers to the dosage of rSP-C in the
PL preparation. This information is not available for other preparations, since they are organic extracts with varying and unknown contents of
hydrophobic apoproteins.burden in the alveolar compartment. A further rationale for
such an approach is provided by various animal models of
acute lung injury in which treatment with surfactant
improved gas exchange and outcome. So far, six pilot
studies addressing the safety and efficacy of trans-
bronchial surfactant administration in ARDS have been
completed (Table 4).
Upon repeated intratracheal administration of Survanta®, a
natural bovine surfactant preparation, with cumulative
doses between 400 and 800 mg/kg body weight (b.w.),
Gregory  et al. noted significant improvement in gas
exchange and obtained a trend towards reduced mortality
in adults with acute respiratory failure [88]. BALF analysis
revealed partially improved surfactant functions.
The safety and efficacy of a bronchoscopic application of
another bovine surfactant preparation (Alveofact®) were
studied in 10 patients with severe, sepsis-induced ARDS,
in an uncontrolled, multicenter study [68]. The surfactant,
300 mg/kg b.w., was delivered through a flexible broncho-
scope in divided doses to each segment of the lung. In
response to the first administration, the PaO2/FiO2
increased from 85 to 200 mmHg (Fig. 3). In some
patients, this improvement in gas exchange was already
evident during the application procedure (Fig. 4). Analysis
of V/Q characteristics (multiple inert gas elimination tech-
nique, MIGET) revealed that treatment resulted in recruit-
ment of formerly collapsed alveoli, reducing the
intrapulmonary shunt flow (from 41.7% at baseline to
19.8% post surfactant) and increasing blood flow through
regions with low and normal V/Q ratios. Patients in whom
the initial increase in PaO2/FiO2 was partially lost received
a second, smaller, dose of surfactant, resulting in pro-
longed improvement of arterial oxygenation. In addition,
the treatment produced a far-reaching, though incomplete,
restoration of the severely altered biochemical and bio-
physical surfactant properties.
In a more recent, phase II, study in Europe and South
Africa, the feasibility and efficacy of a tracheal application
of a surfactant preparation based on recombinant SP-C
(Venticute®) was studied in patients with ARDS [89].
Patients were randomized to receive either standard
therapy alone (STD group) or standard therapy plus recom-
binant SP-C surfactant (MID group, up to 200 mg/kg total
PL, in four doses; HIGH group, up to 500 mg/kg total PL,
in four doses). The MID group showed marked improve-
ments in the oxygenation index (mean PaO2/FiO2 184, vs
139 mmHg in STD), ventilator-free days (mean 10.9, vs 1.8
in STD), and percentage of successfully weaned patients
(57, vs 25 in STD). Finally, mortality was 29% in the MID
and 33% in the STD group. No differences were observed
between the HIGH and STD groups. Very recently, a
phase III trial using this recombinant SP-C-based surfac-
tant was finished. Astonishingly, surfactant treatment did
not result in a significant reduction of ventilator-free days or
mortality (28 days). However, the detailed analysis of this
study is not completed yet.
In another controlled, randomized, unblinded study, the
efficacy of a calf-lung surfactant extract (Infasurf®) was
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Figure 3
Time course of the PaO2/FiO2 ratio in 10 patients with ARDS upon
transbronchial application of 300 and 200 mg/kg body weight of a
surfactant extract from calf lung. ***P < 0.001, as compared with
baseline value. From [68], with permission.
Figure 4
Example of the course of PaO2 in response to transbronchial
surfactant application in an 18-year-old female with severe sepsis-
induced ARDS. The original on-line recording of the PaO2 at a
constant FiO2 of 1.0 after administration of a surfactant extract from
calf lung (Alveofact®, 300 mg/kg body weight) is shown. The PaO2
increased from about 60 mmHg (baseline) to about 220 mmHg after
surfactant application. From [68], with permission.investigated in 42 children with acute respiratory failure
[90], most of them fulfilling ARDS criteria. A rapid
improvement in oxygenation, reduced duration of mechani-
cal ventilation, and an earlier discharge from the pediatric
intensive care unit was observed in the surfactant group.
In contrast to these studies, Anzueto and collegues [91]
found no benefit from an aerosol of a synthetic surfactant
preparation (Exosurf®) in a large, randomized, placebo-
controlled study enrolling 725 patients with sepsis-
induced ARDS. However, there are important criticisms.
Firstly, the aerosolization technique used did not ascertain
a pulmonary deposition of suitably large amounts of sur-
factant. As measured by the authors themselves, only
4.5% of the applied material reached the lungs, thus yield-
ing a daily dose of 5 mg/kg b.w. This dose is two orders of
magnitude below that possibly effective under conditions
of a high alveolar protein burden [26] in ARDS and one
order of magnitude below that currently used in IRDS.
Secondly, Exosurf® is a fully synthetic surfactant prepara-
tion lacking the hydrophobic apoproteins. Apoprotein-free
surfactant preparations have been repeatedly shown to be
less effective in animal studies and IRDS [92] than natural
surfactant preparations and are extremely prone to inhibi-
tion by plasma proteins [93]. In addition, in an attempt to
withdraw the inhibitory plasma proteins from the alveolar
space, Wiswell and colleagues performed a broncho-
alveolar segmental lavage in 12 ARDS patients. For this
purpose surfactant based on a synthetic peptide (KL4),
mimicking SP-B, was used. In essence, the authors
observed an improvement of oxygenation status and posi-
tive end-expiratory pressure (PEEP) level after 72 hours.
However, the lavage procedure resulted in a temporary
(24 hour) deterioration of gas exchange and a need for
higher PEEP levels. These early deleterious effects were
as pronounced as the later beneficial effects [104].
Conclusion
There is good evidence that severe abnormalities of the
pulmonary surfactant system in ARDS contribute to the
pathophysiologic sequelae of the disease. Trans-
bronchial application of exogenous surfactant material
may offer a feasible and safe approach to improve gas
exchange in ARDS and to restore biochemical and bio-
physical properties of the endogenous surfactant pool.
However, a high or repetitive dosage regimen seems
needed to overcome the inhibitory capacities of the
inflamed alveolar space and to achieve a prolonged
recruitment of formerly collapsed lung regions. Further
studies will be needed to elucidate the optimum timing,
dosage regimen, and application technique, and to
establish whether such therapy can reduce mortality in
patients with ARDS. Furthermore, the impact of surfac-
tant on inflammation, host defense, and the fibroprolifera-
tive response in the alveolar compartment will have to be
addressed critically.
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Supplementary Figure 1
Schematic illustration of trigger mechanisms leading to acute respiratory distress syndrome (ARDS). Four key pathophysiological and clinical
findings are encountered in ARDS: firstly, noxious agents may attack the alveolar compartment directly or hit the lung via the intravascular
compartment (indirect, classical ARDS). Secondly, during the early exudative phase, a self-perpetuating inflammatory process involves the entire
gas exchange unit leading to type II cell injury, loss of epithelial (and endothelial) integrity, alveolar edema formation, and severe impairment of
surfactant function. Thirdly, as a result a ventilation-perfusion mismatch with extensive shunt flow is observed. Fourthly, aggravating complications
including new inflammatory events, such as recurrent or persistent sepsis, or acquisition of secondary (nosocomial) pneumonia may repetitively
worsen the state of lung function and then progressively favour proliferative processes characterized by mesenchymal cell activation and ongoing
lung fibrosis. infl., inflammatory, interst., interstitial.Respiratory Research    Vol 2 No 6 Günther et al.
Supplementary Figure 2
Diagram of changes in the surfactant subtype distribution in acute respiratory distress syndrome (ARDS). Under physiological conditions, some
80–90% of the extracellular surfactant material is in the large surfactant aggregate fraction, which has a high surfactant apoprotein B (SP-B)
content and excellent surface activity (γmin; = minimum surface tension after 5 min of film oscillation). In inflammatory lung disease (as in severe
pneumonia or ARDS), the small surfactant aggregates increase as SP-B and surface activity within the large-aggregate fraction decrease.
Supplementary Table 1
Mechanisms of direct or indirect lung injury associated with the development of ARDS
Direct lung injury Indirect lung injury
Most common causes Most common causes
Infection of the lung (viral, bacterial, fungal) Sepsis
Aspiration of gastric contents (Mendelson´s syndrome) Polytrauma with shock and multiple transfusions
Less common causes Less common causes
Near-drowning SIRS (systemic inflammatory response syndrome)
Lung contusion TRALI (transfusion-related acute lung injury)
Inhalation of toxic gases (NO2, ozone, smoke) DIC (disseminated intravascular coagulation)
Exposure to high partial pressure of oxygen Open heart surgery with prolonged extracorporeal circulation 
Intoxication with pulmotropic agents  (e.g. cardiopulmonary bypass)
(bleomycin, paraquat, amiodarone) Acute pancreatitis
High-altitude edema Severe burns
Rapid lung re-expansion (e.g. after puncture of pleura effusions) Fat emboli
Drug intoxication (halothane, heroin)
Head trauma with increased intracranial pressures
Severe forms of malaria, sickle-cell disease